Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | AGE-RAGE signaling pathway in diabetic complications |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
2 | Bladder cancer |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
3 | Chagas disease (American trypanosomiasis) |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
4 | Chemical carcinogenesis |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
5 | Cytokine-cytokine receptor interaction |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
6 | Drug metabolism - cytochrome P450 |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
7 | EGFR tyrosine kinase inhibitor resistance |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
8 | Fatty acid degradation |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
9 | Fluid shear stress and atherosclerosis |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
10 | Focal adhesion |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
11 | Glycolysis / Gluconeogenesis |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
12 | Herpes simplex virus 1 infection |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
13 | HIF-1 signaling pathway |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 | ||
14 | Human cytomegalovirus infection |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
15 | Human papillomavirus infection |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
16 | Inflammatory bowel disease (IBD) |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
17 | Influenza A |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
18 | JAK-STAT signaling pathway |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
19 | Kaposi sarcoma-associated herpesvirus infection |
1件: IFNGR1 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 | ||
20 | Leishmaniasis |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
21 | MAPK signaling pathway |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
22 | Metabolic pathways |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
23 | Metabolism of xenobiotics by cytochrome P450 |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
24 | MicroRNAs in cancer |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
25 | Natural killer cell mediated cytotoxicity |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
26 | Necroptosis |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
27 | Osteoclast differentiation |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
28 | Pancreatic cancer |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
29 | Pathways in cancer |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 | ||
30 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
31 | PI3K-Akt signaling pathway |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
32 | Proteoglycans in cancer |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
33 | Rap1 signaling pathway |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
34 | Ras signaling pathway |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
35 | Relaxin signaling pathway |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
36 | Renal cell carcinoma |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
37 | Retinol metabolism |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
38 | Rheumatoid arthritis |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |
39 | Salmonella infection |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
40 | Th1 and Th2 cell differentiation |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
41 | Th17 cell differentiation |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
42 | Toxoplasmosis |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
43 | Tuberculosis |
2件: IFNGR1, IFNGR2 | D00747 | Interferon gamma-1b | 7件: 65, 85, 90, 228, 299, 301, 326 |
44 | Tyrosine metabolism |
3件: ADH1A, ADH1B, ADH1C | D00707 | Fomepizole | 1件: 301 |
45 | VEGF signaling pathway |
1件: VEGFA | D05697 | Ranibizumab | 4件: 34, 166, 227, 301 |